SCHEMBL6302997

SCHEMBL6302997

CC(C)C(=O)/C=C/c1cc(F)c(F)c(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 5/20 0.43
ALOX5 P09917 2/20 0.41
STAT3 P40763 2/20 0.41
NFE2L2 Q16236 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
EGFR P00533 1/20 0.41
PTGES O14684 1/20 0.40
PTGS1 P23219 1/20 0.40
TUBB1 Q9H4B7 4/20 0.39
PTGS2 P35354 1/20 0.38
CES2 O00748 2/20 0.38
CES1 P23141 2/20 0.38
HDAC1 Q13547 1/20 0.36
APP P05067 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6302999 1.00 CCR2 (0.43) CCR2ALOX5STAT3NFE2L2NFKB1
SCHEMBL6296244 0.83 BACE1 (0.47) ALOX5STAT3NFE2L2NFKB1NFKB2
SCHEMBL6296243 0.83 BACE1 (0.47) ALOX5STAT3NFE2L2NFKB1NFKB2
SCHEMBL6298372 0.82 PTGS2 (0.52) NFE2L2TUBB1PTGS2APPCYP1A2
SCHEMBL6298371 0.82 PTGS2 (0.52) NFE2L2TUBB1PTGS2APPCYP1A2
SCHEMBL584607 0.76 HCAR2 (0.50) ALOX5STAT3NFE2L2NFKB1NFKB2
SCHEMBL584606 0.76 HCAR2 (0.50) ALOX5STAT3NFE2L2NFKB1NFKB2
SCHEMBL6297842 0.76 HSD11B1 (0.62) MEN1KMT2A
SCHEMBL6297840 0.76 HSD11B1 (0.62) MEN1KMT2A
SCHEMBL30572325 0.75 EGFR (0.44) CCR2ALOX5STAT3NFE2L2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075390-A1 HIV protease inhibitors AGOURON PHARMACEUTICALS, INC. 2005-04-07 US disclosed
US-6852711-B2 Novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for AGOURON PHARMACEUTICALS, INC. (US) 2005-02-08 US disclosed
US-20040106606-A1 HIV protease inhibitors BOYER FREDERICK EARL (US) 2004-06-03 US disclosed
US-6528510-B1 Dihydropyrones with tethered heterocycles; 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6 -isopropyl-6-(2-pyridin-4-yl-ethyl)-5,6-dihydro-pyran - 2-one; WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
EP-1112269-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-07-04 EP disclosed
WO-2000015634-A2 HIV PROTEASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106606-A1 HIV protease inhibitors DNPEP, PREP, PEPD CCR2 2498/4885ALOX5 3277/4885STAT3 4144/4885
US-20050075390-A1 HIV protease inhibitors DNPEP, PREP, PEPD CCR2 2501/4885ALOX5 3329/4885STAT3 4110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.